Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus PREMASOL 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 25 IN PLASTIC CONTAINER versus PREMASOL 10 IN PLASTIC CONTAINER.
AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs PREMASOL 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% with dextrose 25% provides amino acids for protein synthesis and dextrose as a carbohydrate calorie source, primarily to prevent protein catabolism and maintain nitrogen balance in patients requiring parenteral nutrition.
Provides essential amino acids for protein synthesis and maintenance of nitrogen balance.
Intravenous infusion: 500 mL to 1000 mL per day, typically at a rate not exceeding 3 mL/kg/hour. Adjusted based on metabolic needs and fluid status.
1-2 g/kg/day intravenously as a continuous infusion or in divided doses; typical starting dose for adults with normal renal function: 1 g/kg/day.
None Documented
None Documented
Amino acids: 0.5-2 hours (plasma clearance). Dextrose: 1.5-2 hours (glucose half-life in normoglycemic patients); clinically, infusion must be continuous to maintain steady state.
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for most amino acids, reflecting rapid metabolism and distribution. Clinically, this supports continuous infusion to maintain plasma amino acid levels.
Renal excretion of amino acids and dextrose metabolites; urea nitrogen accounts for ~80% of nitrogen elimination. Biliary/fecal elimination is negligible for intact components.
Amino acids in Premasol 10% are metabolized and the nitrogen is eliminated primarily as urea via renal excretion (80-90%). A small fraction is excreted in feces (5-10%) and as ammonia in urine. Biliary excretion is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution